News | March 06, 2024
Bayer strengthens pharma portfolio with new cardiology drug acoramidis
Acquisition of exclusive commercialization rights for European markets
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Connecting new production and consumption areas of chilled food by low-carbon transportation services
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
With this, the total number of Patents granted to company for its innovative processes and technology stands at 9
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
BHL will undertake the development and supply of these molecules
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Subscribe To Our Newsletter & Stay Updated
